Skip to content
The Nexus
DossierENTITY

elecoglipron

Coverage of elecoglipron in the Nexus archive.

Earliest in view: Jun 8 · 20:15 UTCMost recent: Jun 8 · 20:15 UTC
Co-mentioned in this coverage
AstraZenecaorganization1VISTAtopic1SOLSTICEtopic1obesitytopic1diabetestopic1Ozempictopic1American Diabetes Associationorganization1Lancetorganization1
Recent coverage
  • HEALTHJun 8 · 20:15 UTCSTAT NEWS
    STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials

    AstraZeneca's investigational GLP-1 pill, elecoglipron, demonstrated significant weight loss in a Phase 2 obesity trial (11.2% after 36 weeks) and improved blood sugar control in a diabetes trial (1.74 percentage-point A1C reduction). Results were compared to oral Ozempic, which showed a smaller A1C decrease in the same study.